Longer OS and a greater ORR, on the other hand, were observed with nivolumab plus ipilimumab across all tumor PD-L1 expression levels, although the benefit was enhanced in the population with ≥1% PD-L1 expression (Table 4). Here, CD274 is linked to neoplasm.